Evidence map›Paper›PMID 26879132›Full record

ArticleBMC cancer2016

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.

Gabriel Schmid, Sara Notaro, Daniel Reimer, Samira Abdel-Azim, Michaela Duggan-Peer, Jessica Holly, Heidi Fiegl, Julia Rössler, Annemarie Wiedemair, Nicole Concin and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Liquid Biopsy in Endometriosis: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Current Advances in RNA Therapeutics for Human Diseases.International journal of molecular sciences · 2022
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Gabriel SchmidDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. gabriel.schmid@i-med.ac.at.
Sara NotaroDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. sara.notaro@hotmail.it.
Daniel ReimerDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. daniel.reimer@i-med.ac.at.
Samira Abdel-AzimDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. Samira.Abdel-Azim@i-med.ac.at.
Michaela Duggan-PeerDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. michaela.peer@i-med.ac.at.
Jessica HollyDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. jessica.holly@i-med.ac.at.
Heidi FieglDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. Heidelinde.Fiegl@i-med.ac.at.
Julia RösslerDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. julia.roessler@uki.at.
Annemarie WiedemairDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. annemarie.wiedemair@uki.at.
Nicole ConcinDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. nicole.concin@i-med.ac.at.
Peter AltevogtSkin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany. p.altevogt@dkfz-heidelberg.de.
Christian MarthDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. Christian.MARTH@tirol-kliniken.at.
Alain Gustave ZeimetDepartment of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. alain.zeimet@uki.at.
Universität Innsbruck · ATInnsbruck Medical University · ATHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target of p53 which is frequently mutated in epithelial ovarian carcinomas especially in high grade serous cancer. Moreover, methylation of miR-34a CpG Islands was found to down-regulate miR-34a expression. The aim of this study was to investigate the clinical relevance of mir34a as well as its promoter methylation in a subset of 133 ovarian cancers with a special focus on the p53 mutation status, the dualistic type I and type II ovarian cancer model and the different histotypes.

methodsOne hundred thirty-three epithelial ovarian cancers and 8 samples of healthy ovarian surface epithelium were retrospectively analysed for miR-34a expression with quantitative real-time reverse transcription PCR (qRT-PCR). Gene-specific DNA methylation was evaluated with MethyLight technique.

resultsSignificantly lower miR-34a expression was found in ovarian cancers than in healthy ovarian epithelium (p = 0.002). The expression of miR-34a was found lower in type II than in type I cancers (p = 0.037), in p53 mutated as compared to p53 wild type cancers (p = 0.003) and in high grade compared to in low grade cancers (p = 0.028). In multivariate COX regression model low expressing miR-34a cancers exhibited a reduced PFS (p = 0.039) and OS (p = 0.018). In serous cancers low miR-34a levels showed a worse OS confirmed also in multivariate analysis (p = 0.022). miR-34a promoter methylation was found higher in type II cancers than in type I (p = 0.006). mir34a expression and promoter methylation showed an inverse correlation in cancer samples (p = 0.05).

conclusionWe demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer.

Indexed as

AgedDNA MethylationFemaleGene Expression Regulation, NeoplasticGene SilencingHumansMicroRNAsMiddle AgedOvarian NeoplasmsOvaryPromoter Regions, GeneticSurvival AnalysisTissue Array AnalysisMicroRNAsMIRN34 microRNA, human

Identifiers

PMID26879132
PMCPMC4754861
OpenAlexW2283712035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.